Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study

Clinical Therapeutics

Volumn 19, Issue 4, 1997, Pages 675-690

  Fish, James E ^a   Kemp, James P ^b   Lockey, Richard F ^c   Glass, Mitchell ^d   Hanby, Laura A ^e   Bonuccelli, Catherine M ^e  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d Zeneca Pharmaceuticals ^*

^e ASTRAZENECA   (United Kingdom)

Author keywords

Asthma; Leukotriene receptor antagonist; Leukotrienes; Zarfirlukast

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; PLACEBO; SALBUTAMOL; ZAFIRLUKAST;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PEAK EXPIRATORY FLOW; PHARYNGITIS; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SINUSITIS;

EID: 0030875339     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80092-6     Document Type: Article

References (20)

1. Djukanovic R, Roche WR, Wilson JW, et al. Mucosal inflammation in asthma. Am Rev Respir Dis. 1990;142:434-457.
2. Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukins in mucosal bronchial biopsies from asthma. J Clin Invest. 1991;87:1541-1546.
3. Broide DH, Lotz M, Cuomo AJ, et al. Cytokines in symptomatic asthmatic airways. J Allergy Clin Immunol. 1992;89:958-967.
4. 4. Proc Natl Acad Sci USA. 1983;80:7626-7630.
5. 4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol. 1988;84:19-26.
6. Chung KF, Barnes PJ. Role of inflammatory mediators in asthma. Br Med Bull. 1992;48:135-148.
7. 4 and histamine in asthmatics. Am Rev Respir Dis. 1992;146: 96-103.
8. 4 from the urine of patients with airway obstruction. Am Rev Respir Dis. 1992;146:104-108.
9. 4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989;1:584-588.
10. 4 in bronchial asthma. Eur Respir J. 1992;5:693-699.
11. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991;143:1025-1029.
12. 4 receptor antagonist. Am Rev Respir Dis. 1992;146:746-749.
13. Dahlén B, Zetterström O, Björck T, Dahlén S-E. The leukotriene-antagonist ICI 204219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J. 1994;7:324-331.
14. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol. 1992;89: 1040-1045.
15. Taylor IK, O'Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991;337:690-694.
16. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med. 1994; 150:618-623.
17. American Thoracic Society Committee on Diagnostic Standards. Definitions and classifications of chronic bronchitis, asthma, and pulmonary emphysema. Am Rev Respir Dis. 1962;85:762-768.
18. Ostle B, Malone LC. Statistics in Research. 4th ed. Ames, Iowa: Iowa State University Press; 1988:47-67, 145-168, 439-448.
19. National Heart, Lung, and Blood Institute. Executive Summary: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Asthma Education Program; 1991. US Department of Health and Human Services, Public Health Service, National Institutes of Health publication No. 91-3042A.
20. Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis. 1993;147:832-838.